Barclays PLC Purchases 30,990 Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL)

Barclays PLC lifted its stake in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) by 130.1% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 54,810 shares of the company’s stock after buying an additional 30,990 shares during the period. Barclays PLC’s holdings in Werewolf Therapeutics were worth $116,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Millennium Management LLC increased its holdings in shares of Werewolf Therapeutics by 96.4% in the second quarter. Millennium Management LLC now owns 1,110,298 shares of the company’s stock worth $2,709,000 after buying an additional 544,881 shares during the period. State Street Corp increased its holdings in shares of Werewolf Therapeutics by 12.4% in the third quarter. State Street Corp now owns 476,439 shares of the company’s stock worth $1,010,000 after buying an additional 52,528 shares during the period. Renaissance Technologies LLC increased its holdings in shares of Werewolf Therapeutics by 103.1% in the second quarter. Renaissance Technologies LLC now owns 171,000 shares of the company’s stock worth $417,000 after buying an additional 86,800 shares during the period. Walleye Capital LLC increased its holdings in shares of Werewolf Therapeutics by 10.7% in the third quarter. Walleye Capital LLC now owns 108,968 shares of the company’s stock worth $231,000 after buying an additional 10,528 shares during the period. Finally, SG Americas Securities LLC purchased a new position in shares of Werewolf Therapeutics in the third quarter worth about $29,000. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Stock Down 7.1 %

HOWL stock opened at $1.44 on Thursday. Werewolf Therapeutics, Inc. has a fifty-two week low of $1.38 and a fifty-two week high of $8.19. The business’s 50 day moving average price is $1.83 and its two-hundred day moving average price is $2.14. The company has a debt-to-equity ratio of 0.29, a quick ratio of 10.10 and a current ratio of 10.10. The company has a market capitalization of $64.17 million, a price-to-earnings ratio of -0.94 and a beta of 0.38.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of Werewolf Therapeutics in a report on Tuesday, November 19th.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.